NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Gain Therapeutics, Inc. (GANX) Stock Analysis

Gain Therapeutics, Inc. (GANX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GANX

$1.19

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GANX with… →

GANX Key Statistics

As of Oct 21, 2026
Trading
Open
$1.20
Previous Close
$1.19
Day's Range
1.15–1.23
52-Week Range
1.15–4.34
Volume
608.96K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19
Valuation
Market Cap
$51.94M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$20.16M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.64M
1-Year Return
−43.33%
Dividend and dates
Avg Volume
460.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GANX closed at $1.19, −43.33% over 1 year.

Gain Therapeutics, Inc. (GANX) has a market capitalization of $51.94M.

In fiscal 2025, GANX reported revenue of $0.00.

GANX Stock Return by Calendar Year

Gain Therapeutics, Inc. (GANX) return since Mar 2021: what $10,000 became

1 year
$10,000 $5,667
−43.33%
5 years
$10,000 $1,667
−83.33%
Since Mar 2021
$10,000 $975
−90.25%

If you had invested $10,000 in Gain Therapeutics, Inc. (GANX) at the close on March 19, 2021, the earliest close on record here, it would have been worth $975 at the close on October 21, 2026: −90.25% in total, −34.05% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−63.04%
2025+49.07%
2024−33.84%
2023+4.31%
2022−42.36%
2021 (partial year)−55.49%

As of October 21, 2026.

GANX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$20.16M—
2024$0.00−$20.41M—
2023$55.18K−$22.27M−40,354.3%
2022$140.11K−$17.59M−12,555.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$18.71M−$20.16M—
2024$0.00—−$20.35M−$20.41M—
2023$55.18K—−$22.25M−$22.27M−40,354.3%
2022$140.11K—−$17.78M−$17.59M−12,555.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Gain Therapeutics, Inc. (GANX) carries a market capitalisation of $51.94M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

The most recent close on file for GANX is $1.19, dated October 21, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $1.15 to $4.34. The latest close sits 3.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $20.16M. Trailing earnings per share are −0.5.

Across the 4 fiscal years on file, revenue moves from $140.11K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −43.33%. Measured over 5 years, that is −30.12% a year compounded. The reported beta is 0.19. Daily returns over the trailing 5 years annualize to a volatility of 86.32%.

Growth & Income

No dividend is on file for GANX.

So far in 2026 the total return is −63.04%. Across the complete calendar years on file, 2025 returned +49.07% and 2022 returned −42.36%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Gain Therapeutics, Inc. (GANX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Gain Therapeutics, Inc. GANX $51.94M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Gain Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Visit website →